IL17B

From WikiMD's WELLNESSPEDIA


IGSF2 (Immunoglobulin Superfamily Member 2), also known as CD101, is a protein encoded by the IGSF2 gene in humans. This protein is a member of the immunoglobulin superfamily, which is characterized by the presence of immunoglobulin-like domains.

Structure[edit]

IGSF2 is a type I transmembrane protein that contains multiple immunoglobulin-like domains. These domains are involved in protein-protein interactions and are crucial for the protein's role in the immune system. The extracellular region of IGSF2 is composed of several Ig-like domains, which are typical of proteins involved in cell adhesion and immune response.

Function[edit]

IGSF2 plays a significant role in the immune system. It is expressed on the surface of various immune cells, including T cells, B cells, and dendritic cells. The protein is involved in the regulation of immune responses, particularly in the modulation of T cell activation and proliferation. IGSF2 has been implicated in the suppression of T cell responses, which suggests a role in maintaining immune homeostasis and preventing autoimmunity.

Clinical Significance[edit]

Alterations in the expression or function of IGSF2 have been associated with various immune-related disorders. For instance, changes in IGSF2 expression have been observed in autoimmune diseases, where the regulation of T cell activity is disrupted. Additionally, IGSF2 may play a role in the immune evasion mechanisms of certain cancers, where its expression can influence the tumor microenvironment and immune surveillance.

Research Directions[edit]

Current research on IGSF2 is focused on understanding its precise role in immune regulation and its potential as a therapeutic target. Studies are exploring how modulation of IGSF2 activity could be used to enhance immune responses against tumors or to suppress unwanted immune activity in autoimmune diseases.

Also see[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.